Leptospira rare outer membrane proteins |
| The present invention presents two novel leptospiral membrane proteins: LipL1 and LipL2. In ... |
|
Interleukin-1 beta converting enzyme like apoptotic protease-6 |
| Toward these ends, and others, it is an object of the present invention to provide polypeptides, ... |
|
Expressed sequence tags and encoded human proteins |
| The present invention relates to purified, isolated, or enriched 5' ESTs which include sequences ... |
|
C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| The invention claimed is: 1. An isolated PC-LECTIN protein comprising the amino acid sequence of SEQ... |
|
Antibodies for use in determining hemoglobin A.sub.1c |
| It is accordingly an object of the present invention to provide a comparatively simple, inexpensive,... |
|
Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives |
| OF THE INVENTION A hapten of the invention is substantially optically pure, and is particularly ... |
|
Immunogens and the use thereof for obtaining antibodies against HBA.sub.1C |
| What is claimed is: 1. Composition of matter consisting essentially of polyclonal antibodies which ... |
|
Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| The present invention overcomes the above mentioned drawbacks and provides methods for treating ... |
|
Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay |
| OF THE INVENTION The present invention is directed to methods for developing and utilizing ... |
|
|
CTLA4/CD28Ig hybrid fusion proteins and uses thereof
| Details |
Inventors: Linsley, Peter S.; Ledbetter, Jeffrey A.; Bajorath, Jurgen; Peach, Robert; Brady, William;
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Primary Examiner: Spector; Lorraine M.
Assistant Examiner:
Attorney, Agent or Firm: Mandel & Adriano
The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins including CTLA4/CD28 chimeric proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions. |
|
DETAILED DESCRIPTION OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to interfere with the binding of the B7 antigen to its ligands such as CD28 and/or CTLA4 thereby obstructing T cell and B cell interaction. As used herein a "B7-binding molecule" means any molecule which will bind the B7 antigen. As used herein an "IL4-binding molecule" means any molecule which will recognize and bind to IL4. As used herein a "CTLA4 mutant" means a molecule having amino acids which are similar to the amino acid sequence of the extracellular domain of CTLA4 so that the molecule recognizes and binds a B7 antigen. As used herein a "CD28 mutant" means a molecule having amino acids which are similar to the amino acid sequence of the extracellular domain of CD28 so that the molecule recognizes and binds a B7 antigen. As used herein a "CTLA4/CD28 hybrid fusion protein" is a molecule having at least portions of the extracellular domains of both CTLA4 and CD28 so that the molecule recognizes and binds a B7 antigen. In order that the invention herein described may be more fully understood, the following description is set forth. This invention is directed to the isolation and expression of the human CTLA4 receptor found on T cell surfaces, which binds to the B7 antigen expressed on activated B cells, and cells of other lineages, and to expression of soluble fusion protein products of the CTLA4 receptor gene. The invention also provides methods for using the expressed CTLA4 receptor to regulate cellular interactions, including T cell interactions with B7 positive cells. In a preferred embodiment, the complete and correct DNA sequence encoding the amino acid sequence corresponding to human CTLA4 receptor protein of the invention is cloned using PCR. The cDNA containing the complete predicted coding sequence of CTLA4 was assembled from two PCR fragments amplified from H38 RNA, and inserted into the expression vector, CDM8 as described in detail in the Examples, infra
|
| Related patents |
|
|
Method of regulating cellular processes mediated by B7 and CD28
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 receptor. The B7 antigen, or its fragments or derivatives are reacted ...
|
|
|
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
This invention is based, at least in part, on the discovery of novel ligands which bind a T cell surface molecule and induce antigen specific apoptosis in an activated T ...
|
|
|
Method for generating and identifying antibodies directed against a B7
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 receptor. The B7 antigen, or its fragments or derivatives are reacted ...
|
|
|
Polypeptide that interacts with heat shock proteins
Described herein are the isolation and characterization of a polypeptide, particularly a tetratricopeptide repeat (TPR)-containing polypeptide that is an interactive ...
|
|
|
1,2-Biguanides
What is claimed is: 1. A substituted biguanide of the formula ##EQU8## wherein R.sub.1 is alkyl of 1-8 carbon atoms, R'.sub.1 is hydrogen or alkyl of 1-8 carbon atoms ...
|
|
|
Biguanide salts
OF THE INVENTION The invention relates to biguanide salts. In another aspect, the invention relates to pharmaceutical preparations which contain the aforementioned ...
|
|
|
Inhibitors of dipeptidyl-aminopeptidase type IV
What is claimed is: 1. A method for treating transplant rejection in a patient comprising administering to said patient an inhibitor of DP-IV, having the structure: ##STR...
|
|
|
Process for preparing anti-obesity protein
OF THE INVENTION For purposes of the present invention, as disclosed and claimed herein, the following terms and abbreviations are as defined below. dDAP--a ...
|
|
|
Use of GLP-1 or analogs to abolish catabolic changes after surgery
The present invention therefore presents for the first time a method of attenuating post-surgical catabolic changes and insulin resistance, comprising, administering to ...
|
|
|
Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury
OF THE INVENTION The present invention provides a method for effective treatment of spinal cord injury. The method involves administering an effective amount of ...
|
|
|